DE60217839T2 - Mittel zur suppression von transplantat-abstossung - Google Patents

Mittel zur suppression von transplantat-abstossung Download PDF

Info

Publication number
DE60217839T2
DE60217839T2 DE60217839T DE60217839T DE60217839T2 DE 60217839 T2 DE60217839 T2 DE 60217839T2 DE 60217839 T DE60217839 T DE 60217839T DE 60217839 T DE60217839 T DE 60217839T DE 60217839 T2 DE60217839 T2 DE 60217839T2
Authority
DE
Germany
Prior art keywords
ailim
antibody
transplantation
human
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60217839T
Other languages
German (de)
English (en)
Other versions
DE60217839D1 (de
Inventor
Seiichi Chiyoda-ku SUZUKI
Mitsuaki Setagaya-ku ISOBE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Application granted granted Critical
Publication of DE60217839D1 publication Critical patent/DE60217839D1/de
Publication of DE60217839T2 publication Critical patent/DE60217839T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Graft Or Block Polymers (AREA)
  • External Artificial Organs (AREA)
  • Transplanting Machines (AREA)
  • Soil Working Implements (AREA)
  • Cylinder Crankcases Of Internal Combustion Engines (AREA)
DE60217839T 2001-03-01 2002-02-05 Mittel zur suppression von transplantat-abstossung Expired - Lifetime DE60217839T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2001056209 2001-03-01
JP2001056216 2001-03-01
JP2001056209 2001-03-01
JP2001056216 2001-03-01
JP2002008028 2002-01-16
JP2002008028 2002-01-16
PCT/JP2002/000930 WO2002070010A1 (fr) 2001-03-01 2002-02-05 Inhibiteurs de rejet du greffon

Publications (2)

Publication Number Publication Date
DE60217839D1 DE60217839D1 (de) 2007-03-15
DE60217839T2 true DE60217839T2 (de) 2007-11-15

Family

ID=27346134

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60235928T Expired - Lifetime DE60235928D1 (de) 2001-03-01 2002-02-05 Mittel zur Suppression von Transplantat-Abstossung
DE60217839T Expired - Lifetime DE60217839T2 (de) 2001-03-01 2002-02-05 Mittel zur suppression von transplantat-abstossung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60235928T Expired - Lifetime DE60235928D1 (de) 2001-03-01 2002-02-05 Mittel zur Suppression von Transplantat-Abstossung

Country Status (24)

Country Link
US (2) US7438905B2 (enExample)
EP (2) EP1374901B9 (enExample)
JP (1) JP4212278B2 (enExample)
KR (1) KR100609444B1 (enExample)
CN (1) CN1518458B (enExample)
AT (2) ATE352318T1 (enExample)
AU (1) AU2002228435B2 (enExample)
BR (1) BR0207787A (enExample)
CA (1) CA2439858C (enExample)
CY (1) CY1110143T1 (enExample)
CZ (1) CZ20032406A3 (enExample)
DE (2) DE60235928D1 (enExample)
DK (1) DK1769807T3 (enExample)
ES (1) ES2344219T3 (enExample)
HU (2) HU228045B1 (enExample)
IL (2) IL156845A0 (enExample)
MX (1) MXPA03006736A (enExample)
NO (2) NO331690B1 (enExample)
NZ (1) NZ527076A (enExample)
PT (1) PT1769807E (enExample)
RU (1) RU2263512C2 (enExample)
SI (1) SI1769807T1 (enExample)
SK (1) SK288048B6 (enExample)
WO (1) WO2002070010A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
CZ20022000A3 (cs) * 1999-12-16 2003-02-12 Teva Pharmaceuticals Industries Ltd. Způsoby přípravy a nová krystalická forma leflunomidu
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
RU2291675C2 (ru) * 2004-07-09 2007-01-20 Институт теоретической и экспериментальной биофизики РАН Способ обработки трансплантатов для сердечно-сосудистой хирургии
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
JP2006321765A (ja) * 2005-05-20 2006-11-30 Mikiko Ueda 肝移植における拒絶反応の予防又は治療薬、或いは拒絶反応とは断定できない肝機能異常の治療薬
EP2068925A4 (en) * 2007-05-07 2011-08-31 Medimmune Llc ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
WO2011007747A1 (ja) 2009-07-16 2011-01-20 大塚化学株式会社 糖鎖付加ａｉｌｉｍ細胞外ドメイン及びその製造方法
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
TW201204334A (en) * 2010-04-12 2012-02-01 Univ Miami Macroporous bioengineered scaffolds for cell transplantation
AU2012233652B2 (en) * 2011-03-31 2017-05-18 Centre Leon Berard Antibodies directed against ICOS and uses thereof
US20150139994A1 (en) * 2013-11-12 2015-05-21 The Regents Of The University Of California Compositions and methods for preventing allogeneic immune rejection
MX378834B (es) * 2013-11-22 2025-03-11 Takeda Pharmaceuticals Co El uso de un inhibidor de c1-esterasa para el tratamiento del rechazo mediado por anticuerpos en pacientes con trasplante de órganos.
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10941446B2 (en) 2014-03-12 2021-03-09 Icahn School Of Medicine At Mount Sinai Method for identifying kidney allograft recipients at risk for chronic injury
CN106661634B (zh) * 2014-06-26 2021-03-12 西奈山伊坎医学院 用于诊断肾异体移植物纤维化和排异风险的方法
AU2015279542B2 (en) 2014-06-26 2021-07-29 Icahn School Of Medicine At Mount Sinai Method for diagnosing subclinical and clinical acute rejection by analysis of predictive gene sets
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
CR20180286A (es) 2015-12-03 2018-07-16 Glaxosmithkline Ip Dev Ltd Dinucleotidos de purina cíclicos como moduladores de sting
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
BR112018070602A2 (pt) 2016-04-07 2019-02-05 Glaxosmithkline Ip Dev Ltd composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
SI3440076T1 (sl) 2016-04-07 2022-09-30 Glaxosmithkline Intellectual Property Development Limited Heterociklični amidi uporabni kot proteinski modulatorji
CA3023157A1 (en) 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
AU2017300123A1 (en) 2016-07-20 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as PERK inhibitors
JP7198752B2 (ja) 2016-08-09 2023-01-04 カイマブ・リミテッド 抗ｉｃｏｓ抗体
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN110573504A (zh) 2017-02-27 2019-12-13 葛兰素史克知识产权开发有限公司 作为激酶抑制剂的杂环酰胺
CA3066048A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
WO2018225035A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
WO2018225034A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
WO2019053613A2 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
TW201927771A (zh) 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 可作為蛋白質調節劑之雜環醯胺及其使用方法
JP7291130B2 (ja) 2017-10-05 2023-06-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
RU2688172C1 (ru) * 2018-04-05 2019-05-20 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ профилактики отторжения трансплантата трупной почки
JP7464279B2 (ja) 2018-04-16 2024-04-09 アイカーン スクール オブ メディスン アット マウント シナイ レシピエント血液における移植前トランスクリプトームシグネチャーを使用した急性拒絶反応および腎臓同種異系移植喪失の予測のための方法およびキット
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
BR112020023459A2 (pt) 2018-05-31 2021-02-23 Glaxosmithkline Intellectual Property Development Limited terapia combinada com proteínas de ligação a icos e inibidores de arginina metiltransferase
EP3801530A1 (en) 2018-05-31 2021-04-14 GlaxoSmithKline Intellectual Property Development Ltd Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer
WO2020031087A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
CN113226369A (zh) 2018-10-22 2021-08-06 葛兰素史克知识产权开发有限公司 给药
US20200368369A1 (en) * 2019-05-22 2020-11-26 Wyvern Pharmaceuticals Inc. Composition for endogenous production of checkpoint protein precursors
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2021046289A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
AU2020355614B2 (en) 2019-09-27 2024-12-05 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
AU2020409429A1 (en) 2019-12-18 2022-06-16 Ctxt Pty Ltd Compounds
CN113294813B (zh) * 2020-02-24 2022-09-02 宁波方太厨具有限公司 一种电磁灶
WO2021209358A1 (en) 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
US20230140694A1 (en) 2020-04-14 2023-05-04 GlaxoSmithKline Intellectual Property Developement Limited Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
AU2021257570A1 (en) 2020-04-14 2022-11-03 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
EP4301733A1 (en) 2021-03-02 2024-01-10 GlaxoSmithKline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
JP2024511831A (ja) 2021-03-31 2024-03-15 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 抗原結合タンパク質およびそれらの組み合わせ
WO2022243378A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
NZ243114A (en) * 1991-06-11 1995-03-28 Blood Res Center Icam-3; dna encoding it; antibodies; hybridomas; pharmaceuticals containing icam-3, a derivative or antagonist, anti-icam-3 or fragment; and in vivo and in vitro diagnosis
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
JP3162438B2 (ja) 1991-09-12 2001-04-25 住友製薬株式会社 高感度特異的抗体測定法
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5747461A (en) * 1994-07-26 1998-05-05 Markov; Angel K. Synergistic administration of cyclosporine and fructose diphosphate
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
PT877626E (pt) 1996-01-23 2003-01-31 Univ Vermont And State Agric C Anticorpos anti-cd1s para utilizacao contra icto
KR20000036207A (ko) 1996-09-18 2000-06-26 스피니엘로 살바토르 자가면역 질환 치료제로서의 단백질의 용도
AU739058B2 (en) * 1996-11-08 2001-10-04 Biogen Idec Inc. Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens
AU4145597A (en) 1997-02-20 1998-09-09 Cedars-Sinai Medical Center Ulcerative colitis panca secretory vesicle antigen and methods of using sa me
FI107538B (fi) * 1997-02-26 2001-08-31 Raisio Benecol Oy Menetelmä stanoliesterien valmistamiseksi
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
WO1999015553A2 (de) * 1997-09-23 1999-04-01 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JPH11228442A (ja) * 1998-02-09 1999-08-24 Cypros Pharmaceut Corp 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用
AU767241B2 (en) * 1998-09-14 2003-11-06 Qiang Xu Immunosuppressive agents
JP2000154151A (ja) * 1998-09-14 2000-06-06 Kyo Jo 免疫抑制剤
CA2346496A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
DK1149114T3 (da) * 1999-02-03 2014-06-23 Amgen Inc Polypeptider, der er involveret ved et immunrespons
BR0010711A (pt) 1999-05-06 2002-02-13 Genetics Inst Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
US6613327B1 (en) 1999-07-28 2003-09-02 Genetics Institute, Inc. Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal
AU6458400A (en) 1999-08-11 2001-03-13 Isis Innovation Limited Nucleic acid, polypeptides, assays, therapeutic methods and means
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) * 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
EP1212343A4 (en) 1999-09-03 2004-11-03 Human Genome Sciences Inc 52 HUMAN SECRETED PROTEINS
JP4737905B2 (ja) 1999-09-21 2011-08-03 ジェネティクス インスティテュート，エルエルシー Ｇｌ５０分子およびその使用
AU1342501A (en) 1999-10-29 2001-05-14 Human Genome Sciences, Inc. 32 human secreted proteins
WO2001064704A1 (en) 2000-03-02 2001-09-07 Mayo Foundation For Medical Education And Research hB7-H2, A NOVEL CO-STIMULATORY MOLECULE
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
WO2002044364A2 (en) 2000-11-28 2002-06-06 Amgen Inc. Polypeptides involved in immune response
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤

Also Published As

Publication number Publication date
NO20110218L (no) 2003-11-03
CZ20032406A3 (cs) 2004-10-13
AU2002228435B2 (en) 2005-03-10
RU2003129166A (ru) 2005-03-10
KR20030078946A (ko) 2003-10-08
EP1769807B1 (en) 2010-04-07
PT1769807E (pt) 2010-06-02
SK288048B6 (sk) 2013-03-01
JP4212278B2 (ja) 2009-01-21
CY1110143T1 (el) 2015-01-14
CA2439858C (en) 2009-07-14
HUP0303332A2 (hu) 2003-12-29
IL156845A (en) 2011-10-31
DK1769807T3 (da) 2010-07-19
NO20033839L (no) 2003-11-03
CA2439858A1 (en) 2002-09-12
SI1769807T1 (sl) 2010-08-31
BR0207787A (pt) 2004-03-23
ATE463256T1 (de) 2010-04-15
NO20033839D0 (no) 2003-08-29
SK12142003A3 (sk) 2004-05-04
US7438905B2 (en) 2008-10-21
WO2002070010A1 (fr) 2002-09-12
IL156845A0 (en) 2004-02-08
NZ527076A (en) 2006-03-31
EP1374901B9 (en) 2007-11-07
US20040253229A1 (en) 2004-12-16
CN1518458A (zh) 2004-08-04
EP1374901A1 (en) 2004-01-02
US20090047292A1 (en) 2009-02-19
HU228108B1 (en) 2012-11-28
HK1061531A1 (en) 2004-09-24
DE60235928D1 (de) 2010-05-20
HK1102293A1 (en) 2007-11-16
ATE352318T1 (de) 2007-02-15
EP1374901B1 (en) 2007-01-24
DE60217839D1 (de) 2007-03-15
NO331690B1 (no) 2012-02-27
HU228045B1 (en) 2012-09-28
CN1518458B (zh) 2010-05-26
EP1769807A1 (en) 2007-04-04
MXPA03006736A (es) 2004-05-31
RU2263512C2 (ru) 2005-11-10
KR100609444B1 (ko) 2006-08-03
EP1374901A4 (en) 2004-09-15
JP2003277293A (ja) 2003-10-02
ES2344219T3 (es) 2010-08-20

Similar Documents

Publication Publication Date Title
DE60217839T2 (de) Mittel zur suppression von transplantat-abstossung
DE69637408T2 (de) Antikörper gegen cd-80
DE69637131T2 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
EP0449769B1 (en) CD 25 binding molecules
DE69636760T2 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
DE69433820T2 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
DE69624436T2 (de) Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
JPH10513348A (ja) ヒトｇｐ３９の種々のエピトープに対して特異的なモノクローナル抗体およびその診断および治療における使用
DE60217698T2 (de) Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex
DE69927831T2 (de) Modulierung von gedächtnis-effector- zellen unter verwendung eines cd2-bindungsagens
DE69825473T2 (de) Cd154-blockadetherapie für das syndrom der hemmung der therapeutischen proteine
DE69428272T2 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
HK1061531B (en) Graft rejection suppressors
HK1102293B (en) Graft rejection suppressors
ZA200306516B (en) Graft rejection inhibitors.
JP2001510027A (ja) Ｔ細胞活性化および増殖を阻害するＬＯ−ＣＤ２ａ抗体およびその用途

Legal Events

Date Code Title Description
8364 No opposition during term of opposition